Royalty Pharma EVP Sells $821,810 in Stock; Company Posts Strong 2025 Results
Marshall Urist, Executive Vice President, Research & Investments at Royalty Pharma PLC (NASDAQ:RPRX), sold 20,000 Class A Ordinary Shares on January 30, 2026, for about $821,810 under a pre-arranged 10b5-1 trading plan. Royalty Pharma reported a record $10 billion in the 2025 royalty funding market, completed its acquisition of PTC Therapeutics’ re…